Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-09
2005-08-09
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231500, C514S252010, C514S254100, C514S256000, C514S326000, C514S336000, C514S367000, C514S365000, C514S372000, C514S378000, C514S381000, C514S383000, C514S393000, C514S406000, C514S444000, C514S451000, C544S060000, C544S149000, C544S238000, C544S333000, C544S374000, C544S405000, C546S284400, C546S192000, C548S152000, C548S215000, C548S240000, C548S255000, C548S267200, C548S254000, C548S364100, C549S060000, C549S292000
Reexamination Certificate
active
06927217
ABSTRACT:
The present invention relates to novel dihydropyrones of Formula Iwherein X is NH or NR8, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.
REFERENCES:
patent: 5789440 (1998-08-01), Ellsworth et al.
patent: 5834506 (1998-11-01), Boyer, Jr. et al.
patent: 0015625 (2000-03-01), None
Navia and McKeever, “A Role for the Aspartyl Protease from the Human Immunodeficiency Virus Type I (HIV-1) in the Orchestration of Virus Assembly”,New York Acad. Sci., 1990; 616:73-85.
von der Helm, “Retroviral Proteases: Structure, Function and Inhibition From a Non-Anticipated Viral Enzyme to the Target of a Most Promising HIV Therapy”,Biol. Chem., 1996;377:765-774.
Deeks et al., “HIV-1 Protease Inhibitors”,JAMA, 1997;277:145-153.
Barry et al., “Protease Inhibitors in Patients with HIV Disease”,Clin. Pharmacokinet., 1997; 32:194-209.
Schock et al., “Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials”,J. Biol. Chem., 1996; 271:31957-31963.
Fätkenheuer et al., “Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients”,AIDS, 1997; 11:F113-F116.
Wallace, “New HIV protease inhibitors”,DDT, 1997; 2:83-84.
Tummino et al., “Discovery and Optimization of Nonpeptide HIV-1 Protease Inhibitors”,Bioorganic&Med. Chem., 1996; 4:1401-1410.
Tait et al., “4-Hydroxy-5,6-dihydropyrones. 2. Potent Non-Peptide Inhibitors of HIV Protease”,J. Med. Chem., 1997; 40:3781-3792.
Hagen et al., “Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity”,J. Med. Chem., 1997; 40:3707-3711.
Vander Roest et al., “Pharmacokinetic evaluation for a series of dihydropyrone HIV protease inhibitors in mice”,37thInterscience Conference on Antimicrobial Agents and Chemotherapy, Sep. 8-Oct. 1, 1997, Toronto, Canada. Abstract 1-84.
Domagala et al., “PD 178390: A Novel Potent Non Peptide HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Class”,5thConference on Retroviruses and Opportunistic Infections, Feb. 1-5, 1998, Chicago, Illinois. Abstract 638.
Thaisrivongs et al., “Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptide Inhibitors”,J. Med. Chem., 1996; 39:4349-4353.
Copending U.S. Appl. No. 09/674,381, filed Oct. 31, 2000.
Boyer, Jr. Frederick Earl
Domagala John Michael
Ellsworth Edmund Lee
Gajda Christopher Andrew
Josyula Vara Prasad Venkata Nagendra
Berch Mark L.
Habte Kahsay
Hutchinson Keith D.
Richardson Peter C.
Warner-Lambert & Company
LandOfFree
HIV protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499295